DocMorris AG shares climbed 5.2% today following the release of a second-quarter 2026 trading update that showed accelerating top-line momentum. The company reported external revenue of CHF 309.7 million, an increase of 15.2% in local currency, a notable step up from the roughly 11% growth rate it posted in the first quarter.
The update highlighted particularly strong performance in Germany, where the prescription drug segment - DocMorris most important growth engine - expanded by nearly 46% year-over-year and also posted sequential acceleration versus the first quarter. DocMorris Digital Services division, which includes TeleClinic, retail media and marketplace activities, rose 80% to CHF 13.9 million.
Management repeated its commitment to achieving adjusted EBITDA breakeven during 2026, and confirmed plans to provide an updated full-year guidance package when it publishes half-year results on August 19.
Investor enthusiasm for the trading update built on an influential analyst action from two sessions earlier. Deutsche Bank upgraded DocMorris to "buy" from "hold" and raised its price target to CHF 11.50 from CHF 5.50, a move the bank said reflected a more attractive risk/reward profile for the stock.
Analyst Jan Koch cited several factors supporting a more constructive view: potential upside to 2026 guidance, lower funding needs, an improved regulatory backdrop, and the underappreciated value of the TeleClinic telemedicine platform. Deutsche Bank argued that the focal point of the investment debate is shifting away from funding and execution risk toward earnings growth, cash flow progress and monetization of the digital health ecosystem.
DocMorris has also outlined an "AI-First" strategic initiative intended to drive operational savings. The plan targets at least CHF 15 million in annual cost reductions through automation and foresees cutting roughly 100 full-time equivalent roles. Management presented this initiative as bolstering the pathway toward free cash flow break-even in 2027.
Competitive dynamics remain a consideration. German drugstore chain Rossmann has announced plans to enter the mail-order pharmacy market, introducing a new competitor in Germany - the primary source of DocMorris revenue. Despite that emerging headwind, investors appeared to place greater weight on the strong Q2 results and strategic actions in driving sentiment.
The broader market environment provided a constructive backdrop for the move. U.S. equities were modestly positive, with the S&P 500 rising 0.1% and the Nasdaq gaining 0.5%, while there was no specific Swiss National Bank policy action or notable Swiss macro release identified as a direct trigger for DocMorris share movement.
Combining an accelerating Q2 performance, a high-conviction analyst upgrade and a credible cost-reduction roadmap drove the stock to an intraday 52-week high of CHF 11.25, a sharp recovery from the 52-week low of CHF 3.92 recorded in late March. Investors appear to be increasingly pricing in the company's progression toward profitability.
Management will provide additional detail on the company's financial outlook with the half-year results on August 19, when the market will have more data to assess progress toward the 2026 adjusted EBITDA breakeven target.